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Preeclampsia is a leading cause of pregnancy complications and affects 3–7% of pregnant
women. This review summarizes the current knowledge of a new potential etiology of
the disease, with a special focus on hemoglobin-induced oxidative stress. Furthermore,
we also suggest hemoglobin as a potential target for therapy. Gene and protein profiling
studies have shown increased expression and accumulation of free fetal hemoglobin
in the preeclamptic placenta. Predominantly due to oxidative damage to the placental
barrier, fetal hemoglobin leaks over to the maternal circulation. Free hemoglobin and its
metabolites are toxic in several ways; (a) ferrous hemoglobin (Fe2+) binds strongly to
the vasodilator nitric oxide (NO) and reduces the availability of free NO, which results
in vasoconstriction, (b) hemoglobin (Fe2+) with bound oxygen spontaneously generates
free oxygen radicals, and (c) the heme groups create an inflammatory response by
inducing activation of neutrophils and cytokine production. The endogenous protein
α1-microglobulin, with radical and heme binding properties, has shown both ex vivo and
in vivo to have the ability to counteract free hemoglobin-induced placental and kidney
damage. Oxidative stress in general, and more specifically fetal hemoglobin-induced
oxidative stress, could play a key role in the pathology of preeclampsia seen both in the
placenta and ultimately in the maternal endothelium.
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INTRODUCTION
Preeclampsia is a clinical syndrome that manifests during the
second half of pregnancy, afflicting 3–7% of pregnant women.
Preeclampsia is one of the leading causes of maternal mortal-
ity and morbidity, especially in developing countries (Mackay
et al., 2001; Berg et al., 2009). The disease is clinically mani-
fested and defined as de novo hypertension with proteinuria after
20 gestational weeks (Redman, 2011). Preeclampsia can develop
into a life-threatening condition with general hemolysis, elevated
liver enzymes, low platelet counts, and elevated levels of free
adult hemoglobin (Hb), classified as the HELLP syndrome (i.e.,
Hemolysis, Elevated Liver enzymes, Low Platelets) (Schroeder
et al., 2002). Preeclampsia can further develop into eclampsia,
a severe complication that is defined by the presence of seizures
(Mackay et al., 2001). Currently, only symptomatic blood pres-
sure treatment is available for preeclampsia and the only known
cure to date is delivery. Hence, preeclampsia causes ∼15% of
pre-term deliveries. Also, in 25% of cases, preeclampsia leads
to intrauterine growth restriction (IUGR) of the fetus. Both
Abbreviations: A1M, alpha-1-microglobulin; IUGR, intrauterine growth restric-
tion; HELLP, hemolysis, elevated liver enzymes, and low platelets syndrome; SOD,
superoxide dismutase; HO, hemoxygenase; O−2 , superoxide; H2O2, hydrogen per-
oxide; ROS, reactive oxygen species; ER, endoplasmatic reticulum; NO, nitric oxide;
sFlt1, soluble fms-like tyrosine kinase 1; VEGF, vascular endothelial growth fac-
tor; PlGF, placental growth factor; TGFβ, transforming growth factor-beta; sEng,
soluble endoglin; RAS, renin-angiotensin system; DIC, disseminated intravascular
coagulation.
pre-term delivery and IUGR result in infant morbidity and sub-
stantial health care expenditure (Shmueli et al., 2012). To date
there is neither a diagnostic test nor screening tool available for
early identification of women at risk of preeclampsia.
Several varying hypotheses and theories regarding the etiol-
ogy have been put forward over the years. One hypothesis, that
was suggested about 25 years ago, is that the extensive vascular
endothelial dysfunction in preeclampsia is the result of circulating
factors released from the placenta (Rodgers et al., 1988; Roberts
et al., 1989). The fact that removal of the placenta is necessary for
symptoms to regress has resulted in the theory that the placenta
is central in the etiology of preeclampsia (Roberts and Hubel,
2009; Roberts and Escudero, 2012). According to the current the-
ory, preeclampsia evolves in two stages. In brief, the first stage
is characterized by a defective placentation, involving incomplete
conversion of the spiral arteries by superficial ingrowth of tro-
phoblasts in the decidua (Brosens et al., 2002). As a consequence,
uneven blood perfusion, hypoxia, and oxidative stress follow. The
second stage of the disease is characterized by the clinical manifes-
tations hypertension, proteinuria, and edema, caused bymaternal
endothelial damage and systemic inflammation. The endothelial
damage is suggested to be caused by placental-derived material
or factors (Roberts et al., 1989; Tjoa et al., 2006; Redman and
Sargent, 2009).
Despite intense research efforts to unveil the etiology of
preeclampsia, it remains enigmatic. However, a growing body of
evidence supports the understanding that the disease begins in
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the utero-placental unit, is amplified by oxidative stress, and ends
in the maternal endothelium.
OXIDATIVE STRESS
Oxidative stress reflects an imbalance between the formation
of oxidative substances and the innate antioxidants that make
up the endogenous defense system. Oxidative substances are
often free oxygen radicals and peroxides that normally form in
small amounts (Buonocore et al., 2010). They can be formed
in e.g., the mitochondrial respiratory chain, and when the tis-
sue is exposed to ischemia/reperfusion injury they are produced
in larger amounts. Due to their highly reactive properties, they
can cause structural and functional damage to cellular DNA, pro-
teins and cell membranes (Tjoa et al., 2006; Valko et al., 2007).
In addition to oxidative stress, nitrative stress has also been doc-
umented in preeclampsia, which is the covalent modification and
nitration of proteins and DNA by peroxynitrite. This occurs in
the preeclamptic placenta by the release of reactive oxygen species
(ROS) such as superoxide, which interacts with nitric oxide (NO)
to form peroxynitrite (Myatt, 2010).
Antioxidants are molecules that inhibit the oxidation caused
by oxidative substances, and they are made up of two sub-groups;
enzymatic and non-enzymatic antioxidants. Examples of enzy-
matic antioxidants are superoxide dismutase (SOD), hemoxyge-
nase (HO), and catalase. SOD’s enzymatic activity catalyzes the
dismutation of superoxide (O−2 ) into oxygen and hydrogen per-
oxide (H2O2) (McCord and Fridovich, 1988). Thus, SOD is an
important antioxidant defense in nearly all cells exposed to oxy-
gen. Three isoforms of HO are known, where HO-1 is inducible
in response to oxidative stress and catalyzes the degradation
of heme. This produces biliverdin, iron, and carbon monoxide
(Kikuchi et al., 2005; Ryter et al., 2006). Catalase is a common
enzyme found in nearly all living organisms exposed to oxy-
gen. It catalyzes the decomposition of H2O2 to water and oxygen
(Chelikani et al., 2004).
Examples of non-enzymatic antioxidants are glutathione,
thioredoxin, NADH, and NADPH. Glutathione is a key endoge-
nous antioxidant that serves several functions, such as neutraliza-
tion of free radicals and ROS (Pompella et al., 2003). In addition,
glutathione also plays a role in keeping vitamins C and E in their
reduced forms (Hughes, 1964; Scholz et al., 1989). Thioredoxin
is an oxidoreductase enzyme containing a dithiol-disulfide active
site that facilitates the reduction of other proteins by cysteine
thiol-disulfide exchange (Holmgren, 1989; Nordberg and Arner,
2001). NADH is a coenzyme found in all living cells, and it
has a role in metabolism where it is involved in redox reactions
(Belenky et al., 2007). NADPH is, among other things, involved
in the protection against ROS by allowing for the regeneration
of reduced glutathione (Rush et al., 1985). The NADPH system
is also responsible for generating free radicals in neutrophils,
which is used in the destruction of pathogens (Ogawa et al.,
2008).
α1-microglobulin (A1M) is both an enzymatic and a non-
enzymatic antioxidant, present both intra- and extracellularly
(Akerstrom and Gram, 2014). It has it’s defensive function by
working as an antioxidant as well as a binding protein for free
radicals and heme (Allhorn et al., 2002; Olsson et al., 2008).
A1M is mainly produced in the liver, but can be found in all
organs. Once produced, it is deployed to the extracellular flu-
ids and compartments via the blood stream. The synthesis of
A1M is up-regulated in response to elevated levels of free rad-
icals, heme, and in particular by free Hb (Olsson et al., 2007).
A1M levels are seen to increase in the preeclamptic placenta in an
effort by the placenta to up-regulate its defense against increased
oxidative stress (Olsson et al., 2010). The protein prevents oxi-
dation and oxidative damage to cells and matrix molecules, and
removes heme from cell membranes and cytosol (Olsson et al.,
2008).
OXIDATIVE STRESS AND PREECLAMPSIA
In preeclampsia, evidence of oxidative stress can be seen both
in the maternal circulation and in the placenta. Placentas from
women with preeclampsia have reduced antioxidant capacity
compared to normal placentas (Wang and Walsh, 1996; Walsh,
1998). Furthermore, levels of antioxidants in blood from women
with preeclampsia have been shown to be reduced, as well as lev-
els of oxidative modifications of proteins and lipoprotein particles
(Hubel, 1999; Raijmakers et al., 2004).
Placental trophoblasts and endothelial cells constitute the pla-
cental barrier, which effectively separates the fetal and maternal
circulation. Oxidative stress and tissue damage is suggested to
cause a breach in the barrier and create a leakage of fetal and
placenta-derived factors and/or material into the maternal cir-
culation. In stage two of the disease the shedding of placental
debris leads to maternal endothelial damage, elevated oxidative
stress, and systemic inflammation (Smarason et al., 1993; Knight
et al., 1998; Hahn and Holzgreve, 2002; Tjoa et al., 2006). An
additional cause to inflammation and vascular damage is the
shedding of microparticles from the placenta, induced by placen-
tal abnormalities and utero-placental ischemia. The content of the
microparticles, such as free Hb and miRNA can further aggra-
vate the systemic oxidative stress (Redman and Sargent, 2008;
Tannetta et al., 2013; Cronqvist et al., 2014; Rudov et al., 2014).
Women living at high altitude alter the normal oxygen balance
and are shown to have increased risk of developing preeclamp-
sia (Palmer et al., 1999). The effect of oxidative stress on female
reproduction has been explored in relation to infertility and
assisted reproductive techniques (Agarwal et al., 2012). Pregnancy
complications such as recurrent pregnancy loss and spontaneous
abortion can develop in response to oxidative stress (Jauniaux
et al., 2000; Poston and Raijmakers, 2004). Maternal obesity has
also been associated with an increased risk of preeclampsia (Wolf
et al., 2001), which could be partly mediated by the increased
level of oxidative stress present in obesity (Zavalza-Gomez, 2011).
Smoking causes oxidative stress and is an established risk fac-
tor for cardio-vascular disease. In pregnant women, smoking
causes increased risk of IUGR. However, smoking has also been
associated with a protective effect against preeclampsia (Conde-
Agudelo et al., 1999). A suggested explanation could be that
the observed lower level of sFlt1 in smokers compared to non-
smokers is due to the suppression of sFlt1 by carbon monoxide
(Karumanchi and Levine, 2010). This is in line with the elevated
levels of sFlt1 observed in womenwith preeclampsia (Levine et al.,
2006).
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OXIDATIVE STRESS CAUSES CELLULAR AND SYSTEMIC
EFFECTS
CELLULAR LEVEL
The degree to which the implantation and the conversion of the
spiral arteries are deficient has been postulated to influence the
degree of oxidative stress and endoplasmic reticulum (ER) stress.
Oxidative stress disturbs the normal redox state of the cell, which
causes toxic effects on all cellular components, including proteins,
lipids, and DNA, and more severe oxidative stress can result in
cell death (Valko et al., 2007). During ER stress, unfolded and
misfolded proteins accumulate in the ER and activate ER stress-
response pathways, also known as the unfolded protein response
(Yung et al., 2014). Preeclamptic placentas have been shown to
accumulate clusters of misfolded proteins and it is speculated that
these aggregates may contribute to the pathophysiology of the dis-
ease. The misfolded proteins can also be detected in urine, as a
potential biomarker by the Congo red dot test (Buhimschi et al.,
2014). ER stress has been shown to be associated with the small
placental phenotype in both preeclampsia and IUGR (Burton
et al., 2009).
SYSTEMIC LEVEL
Inflammation in response to oxidative stress is mediated by
the recruitment of leukocytes and the production of pro-
inflammatory cytokines, adhesion molecules (ICAM-1 and
VCAM-1), and chemokines. This cascade of events is preceded
by the presence of heme, which causes production of ROS
(Lavrovsky et al., 1994; Markus et al., 2007). Heme has also been
shown to induce inflammation via the Toll-like receptors (Belcher
et al., 2014).
Endothelial function is affected by the oxidative burden.
Superoxide inactivates NO, leading to an increase in peroxyni-
trite as well as a reduced bioactivity of NO. Furthermore, free
Hb can also bind NO (Kim-Shapiro et al., 2006). The deple-
tion of NO results in a series of downstream events, such
as impaired endothelium-dependent vasodilation or vasocon-
striction, lipoprotein accumulation and oxidative modification,
intravascular inflammation and release of pro-inflammatory and
vasoactive mediators (Motterlini et al., 1995; Madamanchi et al.,
2005). The contents of placental microparticles released into the
maternal circulation during preeclampsia also contributes to the
elevated level of systemic oxidative stress (Redman and Sargent,
2008; Tannetta et al., 2013; Cronqvist et al., 2014; Rudov et al.,
2014).
Primipara women have an increased risk of preeclampsia while
pre-conception exposure to paternal antigen gives a reduced risk,
implicating an immunological component in the etiology of the
syndrome. During the first stage of preeclampsia, maternal adap-
tation and tolerance to fetal antigen has been suggested to be
crucial (Redman and Sargent, 2010).
ANTIOXIDANT PROTECTIVE SYSTEMS
The human body relies on several antioxidant protective systems.
Uric acid is a powerful antioxidant in the human plasma and
is a scavenger of free oxygen and radicals. It reduces the oxo-
heme oxidant formed by peroxide reaction with Hb and protects
erythrocytes from peroxidative damage leading to lysis (Ames
et al., 1981). The uric acid level both predicts and correlates with
the development of conditions associated with oxidative stress
(Sautin and Johnson, 2008) and is suggested to be a marker for
oxidative stress (Becker, 1993). Therefore, the concentration of
serum uric acid in pregnant women with preeclampsia has been
suggested to be associated with disease severity (Pereira et al.,
2014).
Vitamins C and E are described as antioxidants against oxida-
tive stress, and their effect on the reduced antioxidant capacity in
placentas from women with preeclampsia has been tested in large
randomized trials (Poston et al., 2006; Rumbold et al., 2006; Villar
et al., 2009; Conde-Agudelo et al., 2011). However, supplementa-
tion with vitamins C and E during pregnancy could not be shown
to reduce the risk of preeclampsia (Spinnato, 2006).
The compound magnesium sulfate (MgSO4) is used as a drug
to treat and prevent seizures in severe preeclampsia and eclamp-
sia (Sibai, 2005; Kassie et al., 2014). It has been shown to have
a mild vasodilator effect in the maternal circulation (Sontia and
Touyz, 2007; Souza et al., 2010) as well as a protective effect on
endothelial cells (Kharitonova et al., 2015). It has also been shown
to restore cerebral oxygenation impairment seen in patients with
severe preeclampsia (Guerci et al., 2014). The exact mechanism
of action for MgSO4 is not yet understood, but a role as an
antioxidant has recently been suggested.
From a clinical perspective it would be of great interest to gain
a deeper understanding of the impact of environmental pollu-
tants as well as the influence of nutrients and micronutrients on
the oxidative balance in pregnancy in general and preeclampsia
in particular (Mistry and Williams, 2011). Exposure to air pollu-
tion, especially to ultra-fine particles has been shown to induce
oxidative stress (Terzano et al., 2010). Furthermore, a positive
association between preeclampsia and exposure to air pollutants,
such as nitrogen oxides, nitrogen monoxide, nitrogen dioxide,
carbon monoxide, ozone, particulate matter of <2.5μm and
particulate matter of <10μm, has been shown in recent stud-
ies (Wu et al., 2009, 2011; Lee et al., 2013; Malmqvist et al.,
2013).
Deficiency of micronutrients such as selenium, copper
(Cu), zinc (Zn), and manganese (Mn) during pregnancy can
affect antioxidant capacities in the mother and contribute to
poor pregnancy outcomes e.g., preeclampsia (Rumbold et al.,
2008). The antioxidant defenses found in placenta includes the
selenium-dependent glutathione peroxidases, thioredoxin reduc-
tases, selenoprotein-P, and Cu/Zn and Mn SOD’s (Wang and
Walsh, 1996; Vanderlelie et al., 2005; Rayman, 2009). Studies
have shown a correlation between low serum selenium con-
centrations and reduced antioxidant function in preeclampsia,
suggesting that selenium status is important. This is further sup-
ported by placebo-controlled randomized controls trials where
pregnant women were given selenium supplementation, result-
ing in lower incidence of pregnancy-induced hypertension and/or
preeclampsia (Han and Zhou, 1994; Rumiris et al., 2006). Cu
is an essential cofactor for several important enzymes includ-
ing catalase and SOD (Gambling et al., 2008). Cu is a redox-
active transition metal with pro-oxidant properties and can
catalyze the formation of free radicals, thereby inducing oxida-
tive stress in preeclampsia (Serdar et al., 2006). However, when
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Cu is associated in the Cu/Zn SOD it functions as an antiox-
idant expressed in both maternal and fetal tissue (Ali Akbar
et al., 1998). Studies have shown increased levels of Cu in
placenta, maternal serum, and amniotic fluid in preeclamp-
tic women compared to controls (Brophy et al., 1985; Dawson
et al., 1999; Serdar et al., 2006). However, data on Cu status
throughout normal pregnancies as well as early preeclamptic
pregnancies is inadequate, and it remains unclear whether Cu
deficiency is a public health problem (Arredondo and Nunez,
2005).
Zn has antioxidant functions through the Cu/Zn SOD
(Izquierdo Alvarez et al., 2007). Zn supplementation studies
show reduced incidence of pregnancy induced hypertension
(Goldenberg et al., 1995), and Zn deficiency has been associ-
ated with preeclampsia with decreased levels in placental tissue
and maternal serum (Brophy et al., 1985; Dawson et al., 1999;
Kumru et al., 2003). Mn is also a cofactor for important enzymes,
such as the antioxidant Mn SOD which is involved in protection
against oxidative stress in the placenta (Ademuyiwa et al., 2007).
Studies have indicated that whole blood Mn concentrations are
lower in women with fetal growth restriction (Vigeh et al., 2008).
Furthermore, umbilical cord whole blood in preeclampsia has
been shown to have reduced levels of Mn (Jones et al., 2010).
Dietary nitrate, in e.g., beetroot juice, is converted in vivo to
bioactive nitrogen oxides such as NO and may be used as nitrate
supplementation (Lundberg et al., 2008). It has been shown to
reduce blood pressure, increase blood flow, and modulate oxida-
tive stress (Webb et al., 2008; Carlstrom et al., 2011; Lundberg
et al., 2011). Beetroot juice has recently been shown to improve
placental vascular function during pregnancy in mice (Cottrell
et al., 2014).
FETAL HEMOGLOBIN IN THE PATHOGENESIS OF
PREECLAMPSIA
With the use of microarray and proteomics technologies we
studied gene expression in placentas from normal patients and
patients with preeclampsia. Through the use of a subtraction
library, a total of 750 preeclampsia-associated genes were iden-
tified, which were used to manufacture analytical chips for
microarray analysis (Centlow et al., 2008). Increased expression
of genes involved in inflammation, apoptosis, and oxidative stress
were found in the preeclamptic placentas. More specifically, an
increased expression of fetal Hb (HbF), seen as both elevated
mRNA and accumulation of the protein, was reported (Figure 1).
In situ hybridization and immunohistochemistry were used to
localize the cells that expressed HbF in the placenta, and these
were identified as hematopoietic stem cells located to the vascular
lumen (Figure 1).
FREE HEMOGLOBIN CAUSES OXIDATIVE STRESS
Hb is composed of four globin chains, each with an embed-
ded iron-containing heme group with a high affinity to oxygen.
The most common variants of the globin chains are α, β, and γ,
and that are used differently during normal embryonic and fetal
development. HbF consists of two α- and two γ-chains and is the
main Hb form in fetuses, being expressed from approximately
gestational week 10 to birth. HbF comprises <1% of the Hb in
adults. Adult Hb (HbA) consists of two α- and two β-chains, and
makes up>95% of the Hb after 6 months of age.
The redox activity of the iron atom in the heme group serves
as the basis for the strong oxidative reactivity of free Hb. Free
Hb is defined as extracellular unbound Hb. During hemolysis,
erythrocytes rupture and free Hb leaks out into the circulation.
FIGURE 1 | Increased placental expression of HbF in preeclampsia.
Representative images from in situ hybridizations of human placenta,
displaying the villous section of the placenta. HbF mRNA expression
(α-chain) in a control placenta shown as light field image (A) and as dark
field image (B), and in a preeclamptic placenta shown as light field image
(D) and as dark field image (E). HbF expression was especially seen in
and around blood vessels, with several scattered cells detected in the
villous section of the preeclamptic placenta. HbF protein expression
(γ-chain) is shown with a red fluorescent marker in control placenta (C)
and in preeclamptic placenta (F). In the preeclamptic placenta there is a
strong expression of HbF in the vascular lumen (lu), but HbF is also
expressed in the vascular endothelium (arrow) as well as in the
extravascular section of the villous stroma. The placenta from control
shows no expression of HbF in the vascular lumen (lu), but expression is
detected in the vascular endothelium (arrow). Scale bars for (A,B,D,E) =
100μm and for (C,F) = 25μm. Modified from Centlow et al. (2008).
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Eryptosis is a suicidal erythrocyte death, stimulated by oxidative
stress, energy depletion, calcium imbalance, and a wide range of
xenobiotic compounds. It is inhibited by erythropoietin and NO
(Lang et al., 2012). Eryptosis affects the capillary beds by foster-
ing thrombosis. It is seen in several systemic conditions such as
diabetes, renal insufficiency and malaria, conditions well-known
as risk factors for preeclampsia.
The vasoconstrictive effect of free Hb is a result of the fer-
rous Hb (Fe2+) binding strongly to the vasodilator NO, thereby
reducing the availability of NO. Currently, NO donors are
being investigated in clinical trials as therapeutics for IUGR and
preeclampsia (Cindrova-Davies, 2014). Hb (Fe2+) with bound
oxygen (OxyHb) spontaneously generates free oxygen radicals.
This results in aggregated and oxidized forms of the molecule,
degradation products, and free iron and heme groups. As a result,
Hb and its degradation products are toxic and can cause oxidative
stress, hemolysis, vasoconstriction, kidney, and vascular endothe-
lial damage (Buehler and D’Agnillo, 2010). Heme groups have a
direct effect on the inflammatory response by inducing activation
of neutrophils and induction of cytokine production (Kumar and
Bandyopadhyay, 2005).
Several defense mechanisms exist to protect against the harm-
ful effects of free Hb. Antioxidants such as vitamins C and E pro-
tect against oxidative stress. The blood plasma scavenger proteins
haptoglobin and hemopexin bind free Hb and free heme groups,
respectively, and the formed complexes are eliminated from the
blood by cellular uptake via the two receptor-mediated pathways
CD163 on macrophages and CD91 in the liver (Kristiansen et al.,
2001; Ascenzi et al., 2005). In fact, haptoglobin levels are reduced
in preeclampsia, indicating a depletion of the protective systems
against free Hb (Olsson et al., 2010).
FREE HEMOGLOBIN CAUSES PLACENTAL DAMAGE
Recently our group has shown that free Hb is a potential key fac-
tor in the pathogenesis of preeclampsia. By aggravating oxidative
stress, causing damage to the placental barrier and leaking into the
maternal bloodstream, it causes endothelial damage and vasocon-
striction (Centlow et al., 2008;May et al., 2011). To study the toxic
effect of free Hb on placental tissue, the placenta perfusion model
was used. This well-documented ex vivo system mimics the preg-
nant in vivo situation in humans in a way not possible by using
placenta cell culture or animal models (Schneider and Huch,
1985; Di Santo et al., 2007). In this system, free Hb was added
to the fetal circulation. A preeclampsia-like situation developed
within 10min, displaying a steep increase in blood pressure. Signs
of placental barrier breach appeared after ∼1 h of perfusion, with
leakage of nutrients from the fetal circulation into the maternal
circulation. Transmission electron microscopy (TEM) confirmed
the tissue damage with considerable damage to the extracellular
matrix, with an almost complete elimination of the collagen fib-
rils that maintain the tissue structure (Figure 2). Further, there
were widespread cellular changes with damage to membranes,
nuclei and mitochondria, and formation of apoptotic vesicles
and vacuoles. Gene profiling of placentas perfused with free Hb
showed a similar genetic profile as women with preeclampsia.
These ex vivo findings suggest that free Hb plays an important
role in the disease etiology (Centlow et al., 2009; May et al.,
2011). To further study the effects of free HbF, we established a
pregnant rabbit preeclampsia model where pregnant rabbits were
infused with species-specific free HbF, starting at mid-gestation
until term. TEM analysis of the placenta revealed structural dam-
ages with a dramatic reduction of the collagen fibers in the
extracellular matrix, as well as cellular damages such as mito-
chondrial swelling, aberrant intracellular nuclear membranes,
damaged electron dense barrier, and high levels of apoptotic
bodies (Figure 3). In the pregnant ewe preeclampsia model, star-
vation induces preeclampsia-like symptoms by causing hemolysis
with subsequent release of free Hb (Wester-Rosenlof et al., 2014).
Also in this model TEM analysis could confirm tissue damage in
placentas from starved ewes, with an almost complete elimination
of the collagen fibers as well as cellular damages (Wester-Rosenlof
et al., 2014).
FREE HEMOGLOBIN CAUSES KIDNEY DAMAGE
The proteinuria in preeclampsia is associated with glomeru-
lar injuries in the kidney, known as glomerular endotheliosis.
Endotheliosis includes swelling of endothelial cells and loss of
endothelial fenestration, as well as occlusion of capillary lumens
in some cases (Lafayette et al., 1998; Stillman and Karumanchi,
2007). Podocytes form the slit diaphragm, which is crucial for
maintaining the size-selective nature of the glomerular filtra-
tion barrier in the kidney, and alterations in the podocytes
have been associated with proteinuria in preeclampsia (Garovic
et al., 2007; Henao et al., 2008; Henao and Saleem, 2013).
FIGURE 2 | Free Hb causes placental damage ex vivo which can be
ameliorated by A1M. Transmission electron microscopy analysis of
ex vivo perfused human placenta. (A) Non-perfused human placenta.
(B) Free Hb was added to the fetal circulation and caused severe
damage to the extracellular matrix with an almost complete
elimination of the collagen fibers. (C) A1M was added to the
maternal circulation at the same time as Hb was added to the fetal
circulation, and prevented the damaging effects of Hb on the
extracellular matrix, displaying normal collagen fibers. Scale bars:
200μm. Adapted from May et al. (2011).
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FIGURE 3 | Free HbF causes structural and cellular damage to placenta
tissue in vivo. Transmission electron microscopy analysis of placenta
tissue from pregnant rabbits infused with free HbF. (A,B) Normal placental
tissue from control animals showing extracellular matrix with dense
bundles of collagen fibers. (C,D) HbF causes severe damage to the
extracellular matrix with loss of collagen fibers (indicated by arrows),
extracellular apoptotic bodies, cell debris and a lot of empty extracellular
space (indicated by stars). Scale bars: (A,C) = 500nm; (B,D) = 1μm.
This indicates that podocytes are a crucial part in explain-
ing the loss of filtration capacity in the preeclamptic kidneys.
Podocyturia has also been associated with preeclampsia (Garovic
et al., 2007). Glomerular endotheliosis has long been considered
pathognomonic for preeclampsia (Stillman and Karumanchi,
2007), however, these changes have also been observed, albeit
to a lesser extent, by pregnancy-induced hypertension (absence
of proteinuria) and in normal pregnancy (Strevens et al., 2003).
Furthermore, changes to the podocytes, and their interaction
with the glomerular endothelium has recently been shown to be
important in the onset of proteinuria and podocyturia (Wagner
et al., 2012; Craici et al., 2013). In a mouse knockout model where
podocytes lack VEGF, endotheliosis, and proteinuria were seen
(Eremina et al., 2003). The capillary leakage in the glomeruli con-
tributes to the observed proteinuria. It is further shown that the
renin-angiotensin system (RAS) plays a role in the development
of hypertension by an increased vascular response to angiotensin
II (Wang et al., 2009; Rodriguez et al., 2012). Autoantibodies
against the angiotensin II AT1 receptor has been shown in
preeclampsia (Dechend et al., 2005; Karumanchi and Lindheimer,
2008).
In severe forms of preeclampsia/HELLP/eclampsia, the dam-
aged endothelium activates platelets and the coagulation sys-
tem, whichmay cause sub-acute/acute disseminated intravascular
coagulation (DIC) (Thachil and Toh, 2009). In DIC, there is a
dysregulation of coagulation and fibrinolysis causing decreased
platelet count and fibrinogen levels, and increased consumption
of antithrombin. Especially in the kidneys and the liver, a gradual
fibrin formation occurs.
Patients with preeclampsia exhibit a reduced glomerular fil-
tration rate. Behind this lies a partly reduced renal blood flow
and a reduced filtration area caused by reduced fenestration in
the glomerular endothelium and fibrin deposits. In the HELLP
syndrome, acute kidney injury is seen in approximately 3–15%
of cases (Fakhouri et al., 2012), where glomerular endotheliosis
and acute tubular necrosis are typical findings. The acute high
level of free Hb is likely to contribute to the kidney damage. To
study the effect of free HbF on the function of a normal rat kid-
ney in vivo, free HbF was systemically infused into rats and the
permeability of the glomerular filtration barrier in the kidney
was studied (Sverrisson et al., 2014). Our findings demonstrate
that free HbF induces an increase in the glomerular perme-
ability to macromolecules through the induction of oxidative
stress. This change is believed to occur via a direct interac-
tion between HbF and the endothelium via ROS and/or NO
(Sverrisson et al., 2014). Also, in the pregnant ewe preeclampsia
model, free Hb induced an increase in the glomerular permeabil-
ity as well as typical glomerular endotheliosis (Wester-Rosenlof
et al., 2014) (Figure 4). Other hemolytic diseases such as autoim-
mune hemolytic anemia, sickle cell anemia and malaria are also
known to cause kidney disease (Bunn et al., 1977).
A1M COUNTERACTS TISSUE DAMAGE CAUSED BY FREE Hb
In several recent studies our group has evaluated the protective
effect and the therapeutic potential of A1M. Using the ex vivo
placenta perfusion model described above (May et al., 2011),
preeclampsia-like symptoms developed shortly after perfusion of
free Hb to the fetal circulation. To evaluate the potential thera-
peutic effect, A1M was added to the maternal circulation of the
perfused placenta in an attempt to mimic a potential future intra-
venous therapy. A1M reversed the damages caused by free Hb,
where the Hb leakage from the fetal to the maternal circulation
ceased completely, and no structural damages to the placental tis-
sue were detected (Figure 2). Gene profiling showed that genes
coding for the structural components of the extracellular matrix
were up-regulated, suggesting that a healing process was initiated
by A1M.
The role of A1M was further studied in two different in vivo
animal models. In the first study, systemically infused free HbF
in rats caused an increase in the glomerular permeability to
macromolecules in the kidney through the induction of oxida-
tive stress. This was counteracted by A1M and resulted in a
restored glomerular filtration barrier (Sverrisson et al., 2014).
The pregnant ewe preeclampsia model was also used to evaluate
the therapeutic potential of A1M (Wester-Rosenlof et al., 2014).
In this model, free Hb induced preeclampsia-like symptoms and
intravenous infusion with A1M ameliorated the structural tissue
damages seen in both kidney (Figure 4) and placenta, as well as
restored the glomerular filtration rate in the kidney.
OTHER CONTRIBUTORY FACTORS TO THE DEVELOPMENT OF
PREECLAMPSIA
The maternal injured or activated endothelium in preeclampsia
has been shown to release several factors including endothelin-1,
fibronectin, von Willebrand factor, thrombomodulin, markers of
oxidative stress and inflammatory cytokines (Musci et al., 1988;
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FIGURE 4 | Free Hb causes kidney damage in pregnant ewes which can
be ameliorated by A1M. The renal tissue from starved pregnant ewes was
studied by light microscopy on cortical specimens stained with hematoxylin
and eosin (A–C) and by transmission electron microscopy (D–F). (A) Normal
cortical tissue morphology in control ewes. The renal tubules show minor
signs of postmortem changes but the height of the epithelium is normal, and
only discrete cytoplasmic vacuolization’s are seen. The glomeruli
demonstrate open capillary loops and no signs of segmentation. (B) Clear
signs of glomerular endothelial swelling, seen as closure of capillary loops,
and non-isometric vacuolization of the tubular epithelium in the starved ewes.
(C) In the A1M-treated starved ewes, only small tubular changes compatible
with acute tubular necrosis are present and to a milder degree than seen in
starved ewes. Also, no signs of glomerular endothelial swelling can be seen.
(D) Normal ultrastructure of the glomerular area in control ewes. (E)
Disturbed morphology of the podocytes in the starved animals. The arrows
point at abnormal regions on the basement membrane with fenestrations
underneath. The asterisks mark the basal membrane and P indicates the
podocyte foot extensions. (F) Normalized ultrastructure was observed after
A1M treatment. Magnification: (A,C) 100×; (B) 200×. Scale bars: (D–F)
1μm. Adapted from Wester-Rosenlof et al. (2014).
Thorp et al., 1990; Nova et al., 1991; Taylor et al., 1991; Hsu et al.,
1993; Minakami et al., 1993; Deng et al., 1994; Cackovic et al.,
2008). Other factors with vasodilation properties, e.g., NO and
prostacyclin have been reported to be reduced in preeclampsia
while factors such as angiotensin II and thromboxane have been
shown to be elevated. This imbalance between vasodilation and
vasoconstriction factors contributes to increased vasoconstriction
and hypertension (Lowe, 2000; Ariza et al., 2007).
Endothelial damage also triggers the activation of the coagula-
tion system. Increased thrombocyte activity is seen in preeclamp-
sia, which in severe cases can lead to DIC (Thachil and Toh, 2009).
Thrombosis in the placental vessels further impairs vascular per-
fusion, leading to a negative spiral of illness. In addition, the
leaking fetal and placental factors are usually foreign to the mater-
nal immune system, further contributing to the inflammation
that aggravates the endothelial damage (Rusterholz et al., 2007;
Redman and Sargent, 2009; Messerli et al., 2010).
Signs of chronic inflammation, increased dendritic cell num-
bers and macrophage infiltration are seen in the preeclamptic
placenta, indicating a pathological immune response (Salafia
et al., 1995; Hiby et al., 2004; Lockwood et al., 2006; Huang
et al., 2008). Paternal antigen exposure has been shown to be a
risk factor for preeclampsia. In addition, women with an incom-
plete or disturbed immune system (e.g., untreated HIV positive
women) are less likely to develop preeclampsia, further suggest-
ing an immunological dysfunction to be part of the etiology of
preeclampsia (Wimalasundera et al., 2002).
Another active area of investigation focuses on the role
of angiogenic factors such as sFlt1, VEGF, PlGF, TGFβ, and
sEng in preeclampsia. The maintenance of a healthy vascular
endothelium relies on a proper balance between proangio-
genic and antiangiogenic factors released during pregnancy.
Discordance in these has been postulated to be a possible
cause of endothelial dysfunction seen in preeclampsia (Kendall
and Thomas, 1993; Kendall et al., 1996; Clark et al., 1998;
Wimalasundera et al., 2002; Levine et al., 2006; Sela et al., 2008;
Heydarian et al., 2009; Thomas et al., 2009; Walshe et al., 2009).
CONCLUDING REMARKS
The prevailing theory is that preeclampsia is a syndrome that
starts in the placenta and ends in the maternal endothelium. As
reviewed here, oxidative stress in general, and more specifically
oxidative stress induced by free HbF, could play a key role in the
pathological mechanisms in both the placenta and ultimately the
maternal endothelium as seen in preeclampsia. Gene and protein
profiling studies have shown that free HbF forms and accumulates
in the placenta in preeclampsia.
Oxidative stress appears to hold a central position during
stage one of preeclampsia, and contributes to the clinical man-
ifestations during stage two of the syndrome. Oxidative stress
is amplified in a vicious circle of overproduction and release of
Hb, free HbF in preeclampsia and free HbA in the HELLP syn-
drome. The maternal constitutional factors can either predispose
or protect against the increased oxidative stress. Depending on the
individual constitutional factors, the same oxidative insult may
give rise to several manifestations and forms of preeclampsia, as
well as varying severity.
The endogenous A1M protein, with radical and heme binding
properties, has shown both ex vivo and in vivo to have the ability
to counteract free Hb-induced placental and kidney damage, and
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to restore both placental barrier and glomerular filtration barrier
functions.
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